达格列净治疗心力衰竭的疗效与体重指数关系:DELIVER 试验
DELIVER 试验按 WHO 体重指数(BMI)分类及连续变量分析达格列净对射血分数保留的心力衰竭(HFpEF)患者的疗效。结果显示,达格列净在各 BMI 类别中降低主要结局风险的程度相似(交互 P=0.82),在肥胖患者中症状改善更显著(交互 P=0.03),并带来轻度体重下降(交互 P=0.002)。
要点
- 达格列净降低主要结局风险在各 BMI 类别中一致(交互 P=0.82)。
- 肥胖患者使用达格列净后 KCCQ 症状评分改善更明显(交互 P=0.03)。
- 达格列净带来轻度体重下降,且随 BMI 类别升高更明显(交互 P=0.002)。
核心结论
- 在 HFpEF 患者中,达格列净改善心血管结局的效果跨越 BMI 范围,且在肥胖患者中症状改善更明显并伴有轻度体重下降。
研究设计与样本
- DELIVER 试验的事后分析,按 WHO 的 BMI 分类及连续变量(限制性立方样条)评估达格列净的疗效与安全性。
- BMI 范围 15.2 至 50 kg/m2,均值 29.8(标准差 ±6.1)kg/m2。
- 按 WHO 分类:正常体重 1343 例(21.5%);超重 2073 例(33.1%);I 级肥胖 1574 例(25.2%);II 级肥胖 798 例(12.8%);III 级肥胖 415 例(6.6%)。
主要发现
- 达格列净 vs 安慰剂对主要结局的风险比(95%CI)按上述 BMI 类别依次为:0.89(0.69-1.15)、0.87(0.70-1.08)、0.74(0.58-0.93)、0.78(0.57-1.08)、0.72(0.47-1.08),交互 P=0.82。
- 8 个月时堪萨斯城心肌病问卷(KCCQ)总症状评分安慰剂校正的变化按 BMI 类别依次为:0.9(-1.1, 2.8)、2.5(0.8, 4.1)、1.9(-0.1, 3.8)、2.7(-0.5, 5.8)、8.6(4.0, 13.2)分,交互 P=0.03。
- 12 个月时体重安慰剂校正的变化按 BMI 类别依次为:-0.88(-1.28, -0.47)、-0.65(-1.04, -0.26)、-1.42(-1.89, -0.94)、-1.17(-1.94, -0.40)、-2.50(-4.4, -0.64)kg,交互 P=0.002。
临床怎么用
- 对于 HFpEF 患者,无论 BMI 类别如何,均可考虑使用达格列净以降低心血管结局风险。
- 肥胖的 HFpEF 患者使用达格列净可能获得更明显的症状改善和轻度体重下降。
局限性
- 该分析为 DELIVER 试验的事后分析,BMI 分类结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Obesity is common and associated with unique phenotypic features in heart failure with preserved ejection fraction (HFpEF). Therefore, understanding the efficacy and safety of new therapies in HFpEF patients with obesity is important. The effects of dapagliflozin were examined according to body mass index (BMI) among patients in the Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure trial. METHODS AND RESULTS: Body mass index was analysed by World Health Organization (WHO) categories and as a continuous variable using restricted cubic splines. Body mass index ranged from 15.2 to 50 kg/m2 with a mean value of 29.8 (standard deviation ± 6.1) kg/m2. The proportions, by WHO category, were: normal weight 1343 (21.5%); overweight 2073 (33.1%); Class I obesity 1574 (25.2%); Class II obesity 798 (12.8%); and Class III obesity 415 (6.6%). Compared with placebo, dapagliflozin reduced the risk of the primary outcome to a similar extent across these categories: hazard ratio (95% confidence interval): 0.89 (0.69-1.15), 0.87 (0.70-1.08), 0.74 (0.58-0.93), 0.78 (0.57-1.08), and 0.72 (0.47-1.08), respectively (P-interaction = 0.82). The placebo-corrected change in Kansas City Cardiomyopathy Questionnaire total symptom score with dapagliflozin at 8 months was: 0.9 (-1.1, 2.8), 2.5 (0.8, 4.1), 1.9 (-0.1, 3.8), 2.7 (-0.5, 5.8), and 8.6 (4.0, 13.2) points, respectively (P-interaction = 0.03). The placebo-corrected change in weight at 12 months was: -0.88 (-1.28, -0.47), -0.65 (-1.04, -0.26), -1.42 (-1.89, -0.94), -1.17 (-1.94, -0.40), and -2.50 (-4.4, -0.64) kg (P-interaction = 0.002). CONCLUSIONS: Obesity is common in patients with HFpEF and is associated with higher rates of heart failure hospitalization and worse health status. Treatment with dapagliflozin improves cardiovascular outcomes across the spectrum of BMI, leads to greater symptom improvement in patients with obesity, compared with those without, and has the additional benefit of causing modest weight loss.
引用
- Adamson, Kondo, Jhund, et al. Dapagliflozin for heart failure according to body mass index: the DELIVER trial. Eur Heart J. 2022. PMID: 36029309. doi:10.1093/eurheartj/ehac481
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。